261 related articles for article (PubMed ID: 27450936)
21. Outcomes following partial nephrectomy by tumor size.
Crispen PL; Boorjian SA; Lohse CM; Sebo TS; Cheville JC; Blute ML; Leibovich BC
J Urol; 2008 Nov; 180(5):1912-7. PubMed ID: 18801543
[TBL] [Abstract][Full Text] [Related]
22. Pathological Upstaging of Clinical T1 to Pathological T3a Renal Cell Carcinoma: A Multi-institutional Analysis of Short-term Outcomes.
Nayak JG; Patel P; Saarela O; Liu Z; Kapoor A; Finelli A; Tanguay S; Rendon R; Moore R; Black PC; Lacombe L; Breau RH; Kawakami J; Drachenberg DE
Urology; 2016 Aug; 94():154-60. PubMed ID: 27041471
[TBL] [Abstract][Full Text] [Related]
23. Perioperative epidural analgesia is not associated with increased survival from renal cell cancer, but overall survival may be improved: a retrospective chart review.
Kovac E; Firoozbakhsh F; Zargar H; Fergany A; Elsharkawy H
Can J Anaesth; 2017 Jul; 64(7):754-762. PubMed ID: 28417354
[TBL] [Abstract][Full Text] [Related]
24. Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma.
Margulis V; Tamboli P; Matin SF; Meisner M; Swanson DA; Wood CG
J Urol; 2007 Nov; 178(5):1878-82. PubMed ID: 17868733
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of renal mass biopsy risk stratification algorithm for robotic partial nephrectomy--could a biopsy have guided management?
Rahbar H; Bhayani S; Stifelman M; Kaouk J; Allaf M; Marshall S; Zargar H; Ball MW; Larson J; Rogers C
J Urol; 2014 Nov; 192(5):1337-42. PubMed ID: 24936720
[TBL] [Abstract][Full Text] [Related]
26. Significance of Pathologic T3a Upstaging in Clinical T1 Renal Masses Undergoing Nephrectomy.
Ramaswamy K; Kheterpal E; Pham H; Mohan S; Stifelman M; Taneja S; Huang WC
Clin Genitourin Cancer; 2015 Aug; 13(4):344-349. PubMed ID: 25680295
[TBL] [Abstract][Full Text] [Related]
27. Influence of tumor size on oncological outcomes of pathological T3aN0M0 renal cell carcinoma treated by radical nephrectomy.
Chen L; Ma X; Li H; Gu L; Li X; Gao Y; Xie Y; Zhang X
PLoS One; 2017; 12(3):e0173953. PubMed ID: 28288191
[TBL] [Abstract][Full Text] [Related]
28. Conditional survival of patients with small renal masses undergoing active surveillance.
Petros FG; Venkatesan AM; Kaya D; Ng CS; Fellman BM; Karam JA; Wood CG; Matin SF
BJU Int; 2019 Mar; 123(3):447-455. PubMed ID: 30007044
[TBL] [Abstract][Full Text] [Related]
29. Risk of metastasis for T1a renal cell carcinoma.
Lee H; Lee JK; Kim K; Kwak C; Kim HH; Byun SS; Lee SE; Hong SK
World J Urol; 2016 Apr; 34(4):553-9. PubMed ID: 26245747
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma.
Yoo C; Song C; Hong JH; Kim CS; Ahn H
J Urol; 2008 Aug; 180(2):486-91; discussion 491. PubMed ID: 18550101
[TBL] [Abstract][Full Text] [Related]
31. Adverse pathologic characteristics in the small renal mass: implications for active surveillance.
Syed JS; Nawaf CB; Rosoff J; Bryson C; Nguyen KA; Suarez-Sarmiento A; Serrano M; Kibel AS; Humphrey P; Shuch B; Adeniran AJ
Can J Urol; 2017 Apr; 24(2):8759-8764. PubMed ID: 28436365
[TBL] [Abstract][Full Text] [Related]
32. Percutaneous core biopsy of small renal mass lesions: a diagnostic tool to better stratify patients for surgical intervention.
Menogue SR; O'Brien BA; Brown AL; Cohen RJ
BJU Int; 2013 Apr; 111(4 Pt B):E146-51. PubMed ID: 22805186
[TBL] [Abstract][Full Text] [Related]
33. Extended Duration of Active Surveillance of Small Renal Masses: A Prospective Cohort Study.
Whelan EA; Mason RJ; Himmelman JG; Matheson K; Rendon RA
J Urol; 2019 Jul; 202(1):57-61. PubMed ID: 30932757
[TBL] [Abstract][Full Text] [Related]
34. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma.
Psutka SP; Feldman AS; McDougal WS; McGovern FJ; Mueller P; Gervais DA
Eur Urol; 2013 Mar; 63(3):486-92. PubMed ID: 22959191
[TBL] [Abstract][Full Text] [Related]
35. Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach.
Badalato GM; Kates M; Wisnivesky JP; Choudhury AR; McKiernan JM
BJU Int; 2012 May; 109(10):1457-62. PubMed ID: 21933334
[TBL] [Abstract][Full Text] [Related]
36. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older.
Lane BR; Abouassaly R; Gao T; Weight CJ; Hernandez AV; Larson BT; Kaouk JH; Gill IS; Campbell SC
Cancer; 2010 Jul; 116(13):3119-26. PubMed ID: 20564627
[TBL] [Abstract][Full Text] [Related]
37. Partial nephrectomy for renal masses ≥ 7 cm: technical, oncological and functional outcomes.
Long CJ; Canter DJ; Kutikov A; Li T; Simhan J; Smaldone M; Teper E; Viterbo R; Boorjian SA; Chen DY; Greenberg RE; Uzzo RG
BJU Int; 2012 May; 109(10):1450-6. PubMed ID: 22221502
[TBL] [Abstract][Full Text] [Related]
38. Difference between clinical and pathologic renal tumor size, correlation with survival, and implications for patient counseling regarding nephron-sparing surgery.
Brookman-May S; Johannsen M; May M; Hoschke B; Gunschera J; Wieland WF; Burger M
AJR Am J Roentgenol; 2011 Nov; 197(5):1137-45. PubMed ID: 22021506
[TBL] [Abstract][Full Text] [Related]
39. Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy.
Patel N; Cranston D; Akhtar MZ; George C; Jones A; Leiblich A; Protheroe A; Sullivan M
BJU Int; 2012 Nov; 110(9):1270-5. PubMed ID: 22564495
[TBL] [Abstract][Full Text] [Related]
40. Active surveillance for incidental renal mass in the octogenarian.
Celtik KE; Shah PH; Patel VR; Moreira DM; George AK; Iacovelli V; Alom M; Ng A; Herati A; Salami SS; Bierwiler H; Schwartz MJ; Richstone L; Steckel J; Vira MA; Kavoussi LR
World J Urol; 2017 Jul; 35(7):1089-1094. PubMed ID: 27803967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
